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Objective: To evaluate the efﬁcacy of abiraterone acetate in combination with prednisolone in Taiwanese
men with metastatic castrate-resistant prostate cancer (mCRPC) who failed docetaxel-based
chemotherapy.
Materials and methods: In this single-arm, open label study, 30 mCRPC patients with prostate speciﬁc
antigen (PSA) progression after docetaxel chemotherapy were enrolled. All patients were treated with
abiraterone acetate 1000 mg once daily and prednisolone 5 mg twice daily. The primary end-point was
PSA response rate (deﬁned as proportion of patients achieving a PSA decline of 50%). Secondary end-
points were overall survival and time-to-PSA progression.
Results: Among 28 patients who received one or more cycles of treatment, 15 (53.6%) men achieved PSA
response [95% conﬁdence interval (CI) 33.9e72.5]. The median time-to-PSA progression was 5.5 months
(95% CI 3.1e7.9). The median interval from stopping abiraterone to death was 3.4 months (95% CI 0.1
e21.0), and the median overall survival was 19.2 months (95% CI 13.0e25.4). The PSA responders had
better overall survival compared with PSA nonresponders, in both univariate (log rank test, p ¼ 0.007)
and multivariate (Cox regression, p ¼ 0.001; relative risk: 0.31; 95% CI: 0.12e0.76) analysis. Both a high
Gleason score (8) and viscera involvement did not have an unfavorable response to abiraterone
treatment.
Conclusion: A combination of abiraterone acetate and prednisolone can improve the overall survival in
Taiwanese mCRPC patients who fail prior docetaxel chemotherapy.
Copyright © 2015, Taiwan Urological Association. Published by Elsevier Taiwan LLC. This is an open access
article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Prostate cancer is now the ﬁfth most commonly diagnosed
cancer and is the seventh leading cause of cancer deaths in
Taiwanese men. In 2012, there were 4740 newly diagnosed pa-
tients, with an age-standardized incidence of 29.73/100,000 pop-
ulation.1 A total of 14,769 prostate cancer patients were registeredKaohsiung Veterans General
.
ociation. Published by Elsevier Ta
., The efﬁcacy of abiraterone a
l Science (2015), http://dx.dointo the Taiwan Cancer Registry between 2008 and 2012; among
them 4719 patients (31.95%) were Clinical Stage N1 or M1 and were
treated with androgen-deprivation therapy according to local
guidelines.2 The majority of N1/M1 patients respond well to
androgen-deprivation therapy initially, however, almost all men
will eventually have prostate speciﬁc antigen (PSA) and/or bone
scintiscan progression, despite castrate levels of testosterone. This
is referred to as castrate-resistant prostate cancer (CRPC).3 Histor-
ically, the median survival for men with metastatic CRPC (mCRPC)
has been <2 years.3
Recent studies have shown that despite surgical or medical
castration, adrenal gland and tumor cells may still produceiwan LLC. This is an open access article under the CC BY-NC-ND license (http://
cetate in treating Taiwanese chemo-refractory metastatic castration-
i.org/10.1016/j.urols.2015.11.003
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ceptor signaling pathway.4,5 The key enzyme involved in adrenal
and intratumor androgenic steroid biosynthesis is CYP17.6 Abir-
aterone is a strong, irreversible CYP17 inhibitor. By blocking the
function of 17, 20-lyase, and 17-alpha-hydroxylase, abiraterone
suppresses the biosynthesis of androgen, not only in the adrenal
gland but also in tumor and peripheral tissue, resulting in a
decrease of serum testosterone levels to <1 ng/mL.4e9 In a Phase III
registration trial, abiraterone in combination with prednisolone or
prednisone was shown to prolong overall survival in men with
mCRPC who had received prior docetaxel-based chemo-
therapy.10e12 An overall survival beneﬁt and radiographic free
survival beneﬁt was also shown in a separate Phase III registration
trial in chemotherapy-naïve patients.13,14
Between 2011 and 2013, we carried out a multicenter, open-
label, single-arm, Phase II bridging study in Korea and Taiwan, to
evaluate the safety and efﬁcacy of abiraterone acetate plus pred-
nisolone in an Asian populationwith mCRPC who failed docetaxel-
based chemotherapy (PCR 2007 study).15 A total of 82 patients (52
Korean and 30 Taiwanese) were enrolled. After a median treat-
ment duration of 5.7 months, and a median follow-up time for
survival of 8.3 months, 35 (42.7%) patients achieved a PSA
response [95% conﬁdence interval (CI) 31.8e54.1]. The median
overall survival (from the date of the 1st dose of abiraterone ace-
tate, until the date of death) was 11.8 months.15 Despite a relatively
short treatment and follow-up duration in this study, we found
comparable outcomes with similar studies conducted in Caucasian
populations.5,10
The present study was an extended follow up for the survival
outcome of Taiwanese patients in the PCR 2007 study.2. Materials and methods
2.1. Study population
Patients aged 20 years withmCRPC and documented PSA and/
or image progression after docetaxel chemotherapy were enrolled.
All had Eastern Cooperative Oncology Group performance status
2, and had histologically conﬁrmed adenocarcinoma of the
prostate without neuroendocrine differentiation or small cell his-
tology. Patients on a stable dose of bisphosphonate were allowed to
participate in the study.
Key exclusion criteria included: (1) serious or uncontrolled
coexistent nonmalignant disease, including active and uncontrolled
infection; (2) uncontrolled hypertension, hemoglobin  9.0 g/dL;
(3) abnormal liver function [total bilirubin > 1.5  upper limit of
normal (ULN), aspartate transaminase or alanine
transaminase > 2.5 ULN]; (4) active viral hepatitis or chronic liver
disease; (5) serum creatinine > 2.0  ULN; (6) history of adrenal
insufﬁciency or hyperaldosteronism; and (7) clinically signiﬁcant
heart disease. Patients who were treated previously with ketoco-
nazole were also excluded from the study.
The study protocol was reviewed and approved by our local
institutional review board or ethics committee. All enrolled pa-
tients provided written consent for participation in this study.2.2. Study design
Eligible patients received abiraterone acetate 1000 mg once
daily and prednisolone 5 mg twice daily, orally. Each treatment
cycle consisted of 28 days. Patients continued to receive abiraterone
acetate in combination with prednisolone until disease progres-
sion, unacceptable toxicity, or withdrawal of informed consent for
any reason.Please cite this article in press as: Wu T, et al., The efﬁcacy of abiraterone a
resistant prostate cancer patients, Urological Science (2015), http://dx.do2.3. Efﬁcacy
The PSA response rate (deﬁned as the proportion of patients
achieving a PSA decline of 50% from Cycle 1 Day 1 level) and the
95% CI were calculated based on the treated population (all patients
who received 1 dose of abiraterone acetate). Secondary end-
points included overall survival (deﬁned as the time interval from
the date of the 1st dose of abiraterone acetate, until the date of
death due to any cause) and time-to-PSA progression (deﬁned as
the time interval between the 1st date of abiraterone acetate
treatment and the date of PSA progression). In patients whose PSA
level had never decreased, PSA progression was deﬁned as a 25%
increase over the baseline and an increase in the absolute value by
at least 5 ng/mL; in those whom the PSA had decreased but had not
reached response criteria, progressive disease was deﬁned as an
increase of PSA level by 25% from the nadir and an absolute value by
5 ng/mL; for PSA responders, PSA progression was deﬁned as an
increase of 50% above the nadir and a minimum of 5 ng/mL; all
increases in PSA needed conﬁrmation by a second PSAvalue at least
1 week apart.10
2.4. Statistical analysis
The PSA response rate and the 95% CI were calculated based on
patients who received one or more cycles of abiraterone acetate by
Clopper-Pearson exact method carried out using Daniel Soper
Statistics Calculator version 3 (at DanielScoper.com by Dr. Daniel S.
Scoper at California State University, Fullerton, CA, USA). The overall
survival and time-to-PSA progression was estimated using the
KaplaneMeier method and Cox regression analysis, carried out
using IBM SPSS Statistics version 20 (IBM Corp., Armonk, NY, USA).
3. Results
A total of 30 patients were enrolled from August 2011 to July
2012. The median age of patients was 69 years (range: 55e84
years). Median PSA levels on Cycle 1 Day 1 was 328.5 (range:
8.1e3051.3 ng/mL) ng/mL. Twenty-one patients (70%) had a Glea-
son score of 8. All patients had bone metastasis, 17 (26.7%) had
lymph node involvement, six (20%) had lung metastasis, and four
(13.3%) had liver metastasis (Table 1). All patients had been treated
with a docetaxel-based chemotherapy previously. The median
number of cycles and accumulated dosage of docetaxel was eight
cycles and 800 mg, respectively. Five patients had received second
line chemotherapy; three with cabazitaxel and two with
estramustine.
One patient was withdrawn from the study because of disease
progression, judged by clinical presentation, 1 week after starting
medication. He died of prostate cancer 2 weeks after stopping
abiraterone acetate treatment. One patient withdrew consent 3
days after starting medication because of severe gastrointestinal
discomfort and died 2 months later. The end-points analysis was
calculated based on 28 patients who received one or more cycles of
abiraterone acetate.
At the data cutoff date (31st May 2015), the median treatment
duration was 18 cycles (range: 4e82) and 10 patients (33%)
received >13 cycles (approximately 1 year) of treatment. Reasons
for discontinuing abiraterone acetate included disease progression
(23 patients), adverse events (2 patients), and a serious adverse
event (1 patient with left ventricular dysfunction). Two patients
remained on treatment (>40 cycles) until the data cut-off date,
despite PSA progression.
Twenty-three patients (82.1%) had serum PSA levels start to
decline after one cycle of abiraterone treatment. The PSA nadir was
reached in 13 men (46.4%) on Cycle 3 Day 1 follow up. Overall, 15cetate in treating Taiwanese chemo-refractory metastatic castration-
i.org/10.1016/j.urols.2015.11.003
Figure 1. KaplaneMeier curve of time-to-prostate speciﬁc antigen progression: (A) all
treated patients; (B) Gleason score (Gle)  8 versus Gle  8; and (C) viscera involve-
ment versus bone and lymph nodes only. LNs ¼ lymph nodes; PSA ¼ prostate speciﬁc
antigen.
Table 1
Demographic and baseline characteristics (all treated patients).
n ¼ 30
Age (y)
69 (55e84)
<65 7 (23)
65e74 15 (50)
75 8 (27)
Time from initial diagnosis to ﬁrst dose (mo)
38.9 (16.1e208.4)
Baseline PSA on date of ﬁrst dose (ng/mL)
325.8 (8.1e3051.3)
Gleason score at diagnosis
<7 1 (3)
7 6 (20)
8e10 21 (70)
Unknown 2 (7)
Previous androgen deprivation therapy
Orchiectomy 10 (33)
Medical castration 20 (67)
Evidence of disease progression
PSA only 27 (90)
PSA þ radiographic progression 3 (10)
ECOG performance status
0 16 (53)
1 6 (20)
2 8 (27)
Data are presented as median (range)or n (%).
ECOG ¼ Eastern Cooperative Oncology Group; PSA ¼ prostate speciﬁc antigen.
T. Wu et al. / Urological Science xxx (2015) 1e5 3(53.6%) patients achieved the primary endpoint (95% CI 33.9e72.5)
and seven (25%) patients had90% reduction of PSA. Three patients
never had a PSA decline during treatment with abiraterone acetate.
Based on protocol speciﬁc criteria, the median time-to-PSA
progression was 5.5 months (95% CI 3.1e7.9; Figure 1A). Both a
high Gleason score (8) and visceral involvement did not have a
negative impact on the time-to-PSA progression (log rank test,
p ¼ 0.738 and p ¼ 0.835, respectively; Figures 1B and 1C).
The median follow-up time was 19.3 months (range: 1.9e39.2
months). All 21 deaths were prostate cancer related. The median
interval from stopping abiraterone acetate to death was 3.4 months
(95% CI 0.1e21.0), and the median overall survival was 19.2 months
(95% CI 13.0e25.4). The PSA responders had better overall survival
compared with PSA nonresponders, in both univariate (log rank
test, p ¼ 0.007; Figure 2A) and multivariate (Cox regression,
p ¼ 0.001; hazard ratio: 0.31; 95% CI: 0.12e0.76) analysis. Patients
with a Gleason score  8 and visceral involvement had no signiﬁ-
cant difference in overall survival compared with patients with a
Gleason score < 8 and those without visceral involvement
(p ¼ 0.738 and p ¼ 0.130, respectively; Figures 2B and 2C).
The most common treatment emergent adverse events were
cardiac disorders (27%) and increased blood alkaline phosphatase
levels (27%), followed by hypertension (23%), hypokalemia (23%),
bone pain (20%), and insomnia (20%). Three patients experienced
Grade 3 hypertransaminasemia, one recovered after discontinuing
abiraterone acetate, and two patients did not recover because of
liver metastasis and fatal sepsis.4. Discussion
The present study shows that abiraterone acetate 1000 mg once
daily in combinationwith prednisolone 5mg twice daily achieved a
PSA response rate (50% reduction from the Cycle 1, Day 1 data) in
53.6% of Taiwanese patients with mCRPC postdocetaxel-based
chemotherapy. The PSA response rate was better than that re-
ported in the original article by de Bono et al10 (53.6% vs. 29.1%),
despite the fact that the Taiwanese patients had worse prognosticPlease cite this article in press as: Wu T, et al., The efﬁcacy of abiraterone a
resistant prostate cancer patients, Urological Science (2015), http://dx.dofactors (70% with Gleason score of 8, median PSA level 328.5 ng/
mL).
The majority (82.1%) of patients' serum PSA levels began to
decline after the ﬁrst cycle of abiraterone acetate treatment. All
patients, except the three previously mentioned who never had a
PSA decrease, had PSA levels begin to decline during the ﬁrst three
cycles (12 weeks) of abiraterone acetate treatment. In 14 (50%)
patients, the PSA nadir was reached on Cycle 4, Day 1 follow up.
Based on these ﬁndings, we recommend all patients undergoing
abiraterone acetate treatment should have PSA levels checked after
12weeks of therapy to evaluate the efﬁcacy. For thosewhose serum
PSA had not started to decline, alternative therapy should becetate in treating Taiwanese chemo-refractory metastatic castration-
i.org/10.1016/j.urols.2015.11.003
Figure 2. KaplaneMeier curve of overall survival: (A) prostate speciﬁc antigen re-
sponders versus nonresponders; (B) Gleason score  8 versus < 8; and (C) viscera
involvement versus bone and lymph nodes only. * Median ± standard error (mo).
LNs ¼ lymph nodes; PSA ¼ prostate speciﬁc antigen.
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Cancer Clinical Trials Working Group-2, because treatment should
be continued for at least 12 weeks to ensure adequate drug
exposure.16
Despite a higher PSA response rate, time-to-PSA progression in
Taiwanese patients was much shorter than that observed in the
original COU-AA-301 study (5.5 months vs. 8.5 months).17 The
overall survival in the present study is not inferior to the ﬁnal
analysis of the COU-AA-301 study conducted at a median follow up
of 20 months (19.2 months vs. 15.8 months).17 This discrepancy
might be due to ethnic differences or the extremely small sample
size in our study. Neither a high Gleason score nor visceralPlease cite this article in press as: Wu T, et al., The efﬁcacy of abiraterone a
resistant prostate cancer patients, Urological Science (2015), http://dx.doinvolvement had a negative impact on the treatment efﬁcacy of
abiraterone acetate on mCRPC patients.
Taiwanese patients have a higher incidence of treatment-related
adverse events in hypokalemia, hypertension, increased serum
alkaline phosphatase levels, and transient abnormality in alanine
aminotransferase/aspartate aminotransferase levels compared
with Korean patients or global studies, however, most were Grade 1
or 2 adverse events.12,15 Considering the small sample size, the
difference might not be clinically signiﬁcant. We do recommend
liver function tests and hepatitis markers to rule out active or
chronic liver diseases before prescribing abiraterone acetate. The
serum potassium level should be monitored carefully especially in
the 1st 2e3 months of treatment.
The present study showed that abiraterone acetate in combi-
nation with prednisolone effectively achieved a PSA response rate
in 53.6% of Taiwanese mCRPC patients who failed docetaxel
chemotherapy. The PSA responders had better overall survival
compared with PSA nonresponders. A larger scale study might be
necessary to evaluate whether the Asian population had a shorter
PSA progression-free interval compared with Caucasians.
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